Question: Who's most responsible for infant deaths?
Powered by ReadrBoard: Tell us what you think by highlighting any phrase or comment and adding your reaction.
A few things to know:
• McNeil Consumer Healthcare, the Johnson & Johnson unit that makes Tylenol, and the Food and Drug Administration both knew for 15 years about the sometimes-lethal confusion over its Tylenol products for infants and children. Drop for drop, the strength of Infant’s Tylenol used to far exceed that of Children’s Tylenol. By confusing the products and administering too much of the infant’s version, parents or caretakers could inadvertently overdose their children.
• Aware of the problem, McNeil continued to sell the products as it pleaded with the Food and Drug Administration to add a dosing label that the company believed would solve the problem. The current label instructs consumers to call a doctor to get dosing instructions for children under two — but there is ample evidence that even healthcare providers sometimes mix up the products and give the wrong dosing instructions. McNeil wanted the FDA to add specific instructions by age and weight.
As of 2011, McNeil and other acetaminophen makers voluntarily agreed to stop selling two different concentrations of pediatric products. Today, infants’ and Children’s Tylenol have the same concentration, eliminating the potential confusion between two formulations.
• The FDA, has yet to take formal action. It has not mandated a single concentration. Nor has it decided whether to implement McNeil’s suggestion to add dosing information for kids under two.
Thank you for your interest in republishing this story. You are are free republish the article and graphics so long as you do the following:
You have to credit us — ideally in the byline. We prefer “Author Name, ProPublica.” If your CMS does not allow you to do this, please include a line at the top of the story that reads: “This story was originally published by ProPublica.”
If you’re republishing online, you must link to our website, include all of the links from our story, and use our PixelPing tag.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week,” and “Portland, Ore.” to “Portland” or “here.”)
You cannot republish our photographs or illustrations without specific permission (contact us at [email protected] for more information).
It’s okay to put our stories on pages with ads, but not ads specifically sold against our stories. You can’t state or imply that donations to your organization support ProPublica’s work.
You can’t sell our material separately or syndicate it.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually. (To inquire about syndication or licensing opportunities, contact our Director of Business Development, Celeste LeCompte.)
You can’t use our work to populate a web site designed to improve rankings on search engines, or solely to gain revenue from network-based advertisements.
We do not generally permit translation of our stories into another language.
Any web site our stories appear on must include a prominent and effective way to contact you.
If you share republished stories on social media, we’d appreciate being tagged in your posts. We have official accounts for ProPublica and ProPublica Illinois on both Twitter (@ProPublica and @ProPublicaIL) and Facebook.
Copy and paste the following into your page to republish: